Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
97 hedge funds and large institutions have $50.5M invested in Endocyte, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 13 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
9% less call options, than puts
Call options by funds: $193K | Put options by funds: $211K
5% less funds holding
Funds holding: 102 → 97 (-5)
25% less capital invested
Capital invested by funds: $67.6M → $50.5M (-$17.1M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$593K |
| 2 |
Goldman Sachs
New York
|
+$367K |
| 3 |
DC
Deere & Company
Moline,
Illinois
|
+$233K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$222K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.58M |
| 2 |
State Street
Boston,
Massachusetts
|
-$642K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$489K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$376K |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$347K |
ECYT Hedge Fund Activity: Q1 2016 in Review
97 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2016, worth a combined $50.5M — down 25% from $67.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ECYT and 9 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 28 added.
The largest buyer was Oxford Asset Management, adding an estimated $593K. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.58M.
- 97 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2016, down from 102 in Q4 2015.
- Funds reported $50.5M of Endocyte, Inc. Common Stock stock for Q1 2016, down 25% quarter-over-quarter.
- 9 funds opened new Endocyte, Inc. Common Stock positions in Q1 2016 and 13 closed out, a net change of -4 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q1 2016 was Oxford Asset Management, an estimated $593K added.
- The largest Endocyte, Inc. Common Stock seller in Q1 2016 was Highland Capital Management (Texas), an estimated $1.58M sold.
Based on aggregated 13F filings for Q1 2016.